In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa.
In order to investigate the antimicrobial interactions against multiresistant Pseudomonas aeruginosa, thirty-seven strains resistant to antimicrobial agents of five different chemical classes were exposed in vitro to the combination of three carbapenems. DX-8739, a novel DHP-I stable analogue, meropenem and imipenem with amikacin. The tested combinations expressed an enhanced killing activity against 38-46% of strains and an additive effect against 5-13%. These effects were the same whether the applied carbapenem was DX-8739, meropenem or imipenem; they were also independent of the MIC of any antimicrobial.
Giamarellos-Bourboulis
E J
EJ
1st Department of Propedeutic Medicine, Athens Medical School, Greece.
Grecka
P
P
Giamarellou
H
H
D000583:Amikacin / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015780:Carbapenems / Q000494:pharmacology*; D004347:Drug Interactions; D018432:Drug Resistance, Multiple; D015378:Imipenem / Q000494:pharmacology*; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D013845:Thienamycins / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D015780:Carbapenems; C094221:DX 8739; D013845:Thienamycins; D015378:Imipenem; D000583:Amikacin; D000077731:Meropenem